Abstract:Background The inflammatory biomarker YKL‐40 has previously been studied as a potential risk marker in cardiovascular disease. We aimed to assess the prognostic reclassification potential of serum YKL‐40 in patients with stable coronary artery disease. Methods and Results The main study population was the placebo group of the CLARICOR (Effect of Clarithromycin on Mortality and Morbidity in Patients With Ischemic Heart Disease) trial. The primary outcome was a composite of acute myocardial infarction, unstable angina pectoris, cerebrovascular disease, and all‐cause mortality. We used Cox proportional hazards regression models adjusted for C‐reactive protein level and baseline cardiovascular risk factors. Improvement in prediction by adding serum YKL‐40 to the risk factors was calculated using the Cox‐Breslow method and c‐statistic. A total of 2200 patients were randomized to placebo, with a follow‐up duration of 10 years. YKL‐40 was associated with an increased risk of the composite outcome (hazard ratio per unit increase in (YKL‐40) 1.13, 95% CI 1.03–1.24, P =0.013) and all‐cause mortality (hazard ratio 1.32, 95% CI 1.17–1.49, P <0.0001). Considering whether a composite‐outcome event was more likely to have, or not have, occurred to date, we found 68.4% of such predictions to be correct when based on the standard predictors, and 68.5% when serum YKL‐40 was added as a predictor. Equivalent results were obtained with c‐statistics. Conclusions Higher serum YKL‐40 was independently associated with an increased risk of adverse cardiovascular outcomes and mortality. Addition of YKL‐40 did not improve risk prediction in patients with stable coronary artery disease. Clinical Trial Registration URL: https://www.clinicaltrials.gov/ . Unique identifier: NCT00121550. Clinical Perspective What Is New? In patients with stable coronary artery disease, higher YKL‐40 is significantly related to cardiovascular events and mortality over 10 years of follow‐up after adjustment for standard predictors and high‐sensitivity C‐reactive protein, possibly reflecting high‐risk atherosclerotic progression and inflammation. What Are the Clinical Implications? In reclassification analysis YKL‐40 did not improve prognostic accuracy compared with predictions based only on standard predictors, and the value of measuring YKL‐40 to support clinical decision making appears limited. Introduction The desire to better assess prognosis in patients with cardiovascular disease (CVD) and further advance the understanding of the underlying atherosclerotic process has prompted the emergence of numerous potential CVD biomarkers. Many candidates have demonstrated consistent association with standard CVD outcome measures. Nonetheless, auxiliary predictive potential in addition to that offered by standard available clinical characteristics is in many cases absent or unclear, hindering translation of results into specific changes in patient management strategies. 1 , 2 , 3 However, in addition to possible utility in risk prediction, biomarker studies may unravel new key factors in CVD pathogenesis such as proinflammatory effectors, and ultimately help identify new potential upstream treatment targets. 4 , 5 YKL‐40, also known as chitinase‐3‐like‐1, is an inflammatory biomarker which has gathered increasing evidence during the past 2 decades. 6 It is considered an acute‐phase protein and has been specifically linked to the inflammatory process in the atherosclerotic plaque, 7 diseases of extracellular remodeling and fibrosis, 8 angiogenesis and regulation of proinflammatory cascades. 9 , 10 YKL‐40 has recently been associated with development of hyperlipidemia and ischemic stroke in a study of almost 10 -Abstract Truncated-

Plasma Human Cartilage Glycoprotein-39 Is Associated With the Prognosis of Acute Ischemic Stroke

Prognostic Performance of Serum YKL-40 for One-Year Clinical Outcomes in Acute Ischemic Stroke

Plasma gelsolin levels and 1-year mortality after first-ever ischemic stroke

Alcohol Drinking Modified the Effect of Plasma YKL-40 Levels on Stroke-specific Mortality of Acute Ischemic Stroke

The Relationship Between Serum YKL-40 Levels on Admission and Stroke-Associated Pneumonia in Patients with Acute Ischemic Stroke

Causal Effects of YKL‐40 on Ischemic Stroke and Its Subtypes: A 2‐sample Mendelian Randomization Study

Plasma Interleukin-37 is Elevated in Acute Ischemic Stroke Patients and Probably Associated With 3-month Functional Prognosis

Plasma homeostatic chemokines CCL19 and CCL21 and the prognosis of ischemic stroke in two Chinese prospective cohorts

Interleukin-6 and YKL-40 predicted recurrent stroke after ischemic stroke or TIA: analysis of 6 inflammation biomarkers in a prospective cohort study

Plasma Neuropeptide Y Levels and Adverse Clinical Outcomes after Acute Ischaemic Stroke.

Serum YKL-40 as a Predictive Biomarker of Cerebral Amyloid Angiopathy-Related Intracerebral Hemorrhage Recurrence

Prognosis and Reclassification by YKL-40 in Stable Coronary Artery Disease.

Plasma Phenylacetylglutamine Levels and Prognosis of Ischemic Stroke: A Multicenter Prospective Study Based on the CATIS Trial

YKL-40 Is Associated With Ultrasound-Determined Carotid Atherosclerotic Plaque Instability

Angiopoietin‐like Protein 4 and Clinical Outcomes in Ischemic Stroke Patients

Prognostic Value of Plasma HMGB1 in Ischemic Stroke Patients with Cerebral Ischemia-Reperfusion Injury after Intravenous Thrombolysis.

Serum Hepatocyte Growth Factor is Probably Associated with 3-Month Prognosis of Acute Ischemic Stroke

Increased serum YKL-40 and C-reactive protein levels are associated with angiographic lesion progression in patients with coronary artery disease

Increased serum interleukin-34 levels as a novel diagnostic and prognostic biomarker in patients with acute ischemic stroke

Plasma S100A8/A9 Concentrations and Clinical Outcomes of Ischemic Stroke in 2 Independent Multicenter Cohorts.

HS‐CRP Modifies the Prognostic Value of Platelet Count for Clinical Outcomes after Ischemic Stroke